Business
AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy-parkinsonian type (MSA-P)Completion of enrollment marks a significant milestone in progression of MSA-P clinical program and follows significant AB-1005 Parkinson’s disease program updates AskBio Inc. (AskBio), a gene therapy company
About this update from Bayer Ag
[{"type":"text","content":"Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) --","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy-parkinsonian type (MSA-P)","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Completion of enrollment marks a significant milestone in progression of MSA-P clinical program and follows significant AB-1005 Parkinson’s disease program updates ","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":389,"olType":false},{"type":"text","content":"AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced the completion of enrollment for REGENERATE MSA-101, its Phase 1 clinical trial of AB-1005, an investigational gene therapy being developed as a treatment for multiple system atrophy-parkinsonian type (MSA-P).1","length":340,"tagName":"p"},{"type":"text","content":"The completion of enrollment marks a significant milestone in the development of AB-1005, an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, and it brings this potential treatment option one step closer to reaching the many patients affected by MSA-P.","length":372,"tagName":"p"},{"type":"text","content":"MSA-P can initially be difficult to distinguish from Parkinson’s disease and is marked by slow movement, lack of coordination, imbalance, dizziness, and fainting, among other symptoms.2 Individuals experience increasing difficulty with movement and autonomic dysfunction.2 This is a result of progressive loss of nerve cells in the brain and spinal cord.2 Affecting approximately 400,000 people worldwide, MSA is a rare disease that in most cases seems to occur for unknown reasons.2,3,4 Symptoms tend to develop in people over 50 years of age, followed by rapid progression within 5–10 years.2","length":594,"tagName":"p"},{"type":"text","content":"“There is currently no disease-modifying treatment to stop or slow the progression of MSA, which makes the completion of enrollment in REGENERATE MSA-101 an important...